Company News

Respiratory infections remain a significant challenge for patients, healthcare professionals, and healthcare systems worldwide. From seasonal respiratory illnesses to more severe infections, clinicians often face complex decisions when evaluating patients whose similar symptoms can have many possible causes.

For patients at risk of sepsis, time matters. Faster diagnostic information can help healthcare teams identify the cause of infection sooner, supporting earlier better-informed care decisions.

With GENE-UP® PROBIOTIC SPECIES ID, bioMérieux introduces a first-of-its-kind commercialized species-level identification PCR solution for in-house quality control teams and external laboratory partners.

Our products’ environmental performance is a core pillar of our commitment to protecting the planet. For several years, bioMérieux has been implementing a continuous improvement approach based on Life Cycle Assessments (LCAs) of our diagnostic solutions. The goal is to measure our products’ impact on the climate and environment across the entire value chain — from manufacturing and customer use to end-of-life management.

In line with our public health mission, bioMérieux and BioFire Defense, a bioMérieux company, are mobilizing Ebola diagnostics to support ongoing efforts related to the current Ebola outbreak in Africa.